Literature DB >> 16133411

Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours.

C Matheï1, E Wollants, J Verbeeck, M Van Ranst, G Robaeys, P Van Damme, F Buntinx.   

Abstract

The aim of this study was to determine the genotypic variation of hepatitis C among drug users in Flanders and to relate the distribution of genotypes to the characteristics of the population. Hepatitis C virus RNA (HCV-RNA) quantification and genotyping was performed on stored samples from 161 anti-HCV-positive injecting and non-injecting drug users. Information on sociodemographic status, drug-related risk behaviour and sexual risk behaviour was available for each drug user. HCV-RNA was present in 152 of 161 samples (94.4%). Genotype 1 was predominant (48.7%), followed by genotype 3 (41.2%), genotype 4 (8.8%) and genotype 2 (1.4%). In the multivariate analysis, lack of a history of injecting drug use was confirmed as a statistically significant predictor for infection with genotype 1. Predictors for infection with genotype 3 were the presence of anti-HBc antibodies and a history of injecting drug use. Being tattooed emerged as a statistically significant predictor for infection with genotype 4. The 94.4% prevalence of HCV-RNA among anti-HCV-positive drug users was considerably higher than the 54-86% chronicity rate found globally among HCV-infected patients. The results of this study suggest the existence of separate transmission networks for injecting drug users and non-injecting drug users. Finally, the results suggest that tattooing practices play a role in the spread of HCV among drug users.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133411     DOI: 10.1007/s10096-005-1376-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  69 in total

1.  Hepatitis C virus infection in young, low-income women: the role of sexually transmitted infection as a potential cofactor for HCV infection.

Authors:  Kimberly A Page-Shafer; Barbara Cahoon-Young; Jeffrey D Klausner; Scott Morrow; Fred Molitor; Juan Ruiz; Willi McFarland
Journal:  Am J Public Health       Date:  2002-04       Impact factor: 9.308

2.  The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a.

Authors:  K A Harris; C Gilham; P P Mortimer; C G Teo
Journal:  J Med Virol       Date:  1999-06       Impact factor: 2.327

3.  Is the prevalence of hepatitis C virus (HCV) RNA in anti-HCV-positive injection drug users positively correlated with age?

Authors:  C Matheï; F Buntinx; P Van Damme
Journal:  J Infect Dis       Date:  2001-09-01       Impact factor: 5.226

Review 4.  Epidemiology of hepatitis C virus infection among injecting drug users in Australia.

Authors:  N Crofts; D Jolley; J Kaldor; I van Beek; A Wodak
Journal:  J Epidemiol Community Health       Date:  1997-12       Impact factor: 3.710

5.  The epidemic behavior of the hepatitis C virus.

Authors:  O G Pybus; M A Charleston; S Gupta; A Rambaut; E C Holmes; P H Harvey
Journal:  Science       Date:  2001-06-22       Impact factor: 47.728

6.  Sharing of drug preparation equipment as a risk factor for hepatitis C.

Authors:  H Hagan; H Thiede; N S Weiss; S G Hopkins; J S Duchin; E R Alexander
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

7.  High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts.

Authors:  I Diamantis; S Bassetti; P Erb; D Ladewig; K Gyr; M Battegay
Journal:  J Hepatol       Date:  1997-04       Impact factor: 25.083

8.  Clinical presentation of GB-C virus infection in drug abusers with chronic hepatitis C.

Authors:  T Goeser; S Seipp; R Wahl; H M Müller; W Stremmel; L Theilmann
Journal:  J Hepatol       Date:  1997-03       Impact factor: 25.083

9.  Association between hepatitis C virus seroreactivity and HIV infection in non-intravenous drug abusing prostitutes.

Authors:  J A Pineda; A Rivero; C Rey; J Hernández-Quero; A Vergara; J Muñoz; I Aguado; J Santos; R Torronteras; J A Gallardo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

10.  Hepatitis C virus (HCV) genotype distribution in German isolates: studies on the sequence variability in the E2 and NS5 region.

Authors:  G Driesel; D Wirth; K Stark; R Baumgarten; U Sucker; E Schreier
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

View more
  12 in total

1.  HCV genotype distribution in Flanders and Brussels (Belgium): unravelling the spread of an uncommon HCV genotype 5a cluster.

Authors:  J Verbeeck; L Kwanten; F D'Heygere; A Beguin; S Michiels; I Desombere; G Leroux-Roels; P Lemey; F Nevens; M Van Ranst
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-10       Impact factor: 3.267

2.  Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon.

Authors:  Ziyad Mahfoud; Kassem Kassak; Khalil Kreidieh; Sarah Shamra; Sami Ramia
Journal:  Virol J       Date:  2010-05-13       Impact factor: 4.099

Review 3.  Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients.

Authors:  David M Novick; Mary Jeanne Kreek
Journal:  Addiction       Date:  2008-04-16       Impact factor: 6.526

Review 4.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

5.  Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California.

Authors:  Paulo Telles Dias; Judith A Hahn; Eric Delwart; Brian Edlin; Jeff Martin; Paula Lum; Jennifer Evans; Alex Kral; Steve Deeks; Michael P Busch; Kimberly Page
Journal:  BMC Infect Dis       Date:  2011-08-02       Impact factor: 3.090

6.  Molecular epidemiology of hepatitis C infection in Cyprus within the general population and high-risk cohorts.

Authors:  Victoria L Demetriou; Leondios G Kostrikis
Journal:  BMC Res Notes       Date:  2011-10-31

7.  Identification of Patients with Hepatitis C Virus Infection in Persons with Background of Intravenous Drug Use: The First Community Announcement-based Study From Iran.

Authors:  Reza Fadaei Nobari; Marjan Meshkati; Behrooz Ataei; Mohammad Reza Yazdani; Kamal Heidari; Nazila Kassaian; Zary Nokhodian; Parisa Shoaei; Majid Yaran; Peyman Adibi
Journal:  Int J Prev Med       Date:  2012-03

8.  Quantifying hepatitis C transmission risk using a new weighted scoring system for the Blood-Borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ): applications for community-based HCV surveillance, education and prevention.

Authors:  Mark A Stoové; Craig L Fry; Nicholas Lintzeris
Journal:  Harm Reduct J       Date:  2008-04-23

Review 9.  Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.

Authors:  Lucas Wiessing; Marica Ferri; Bart Grady; Maria Kantzanou; Ida Sperle; Katelyn J Cullen; Angelos Hatzakis; Maria Prins; Peter Vickerman; Jeffrey V Lazarus; Vivian D Hope; Catharina Matheï
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

10.  Changes in hepatitis C virus genotype distribution in Japan.

Authors:  H Toyoda; T Kumada; K Takaguchi; N Shimada; J Tanaka
Journal:  Epidemiol Infect       Date:  2014-03-05       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.